$ATRX MLR-1023 is a next generation, non-PPAR insulin sensitizer via lyn kinase activation that has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and 2b diabetes studies. Dr. Buteau has a deep understanding of the mechanism of action of MLR-1023 through his research proving the potent effect of MLR-1023 to have influence on pancreatic beta cell protection and proliferation in vitro and in mouse models of T1D, which is theorized to potentially translate to delaying or preventing T1D in humans. A new effective, safe treatment would be a major leap forward for a disease affecting approximately 9 million people worldwide,1 including more than 2 million people in North America2,3 that rely upon insulin injections to manage their disease.